Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers

Hye Soo Kim, Oidov Baatarkhuu, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang Hyub Han, Beom Kyung Kim, Seung Up Kim

Research output: Contribution to journalArticle

Abstract

Background & Aims: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). Methods: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. Results: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). Conclusions: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalLiver International
Volume39
Issue number1
DOIs
Publication statusPublished - 2019 Jan

Fingerprint

Chronic Hepatitis B
Fibrosis
Liver
Pharmaceutical Preparations
Hepatocellular Carcinoma
Inflammation

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{2954c31b6ba945a790a2b355a7de2f12,
title = "Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers",
abstract = "Background & Aims: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). Methods: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. Results: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4{\%} in NUC-VR group vs 3.3{\%} in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0{\%} vs 4.3{\%}, PSM model-1 (612 pairs); 3.7{\%} vs 4.4{\%}, PSM model-2 (618 pairs); and 2.4{\%} vs 4.3{\%}, PSM model-3 (610 pairs)] (all P > 0.05). Conclusions: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.",
author = "Kim, {Hye Soo} and Oidov Baatarkhuu and Lee, {Hye Won} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Kijun Song and Han, {Kwang Hyub} and Kim, {Beom Kyung} and Kim, {Seung Up}",
year = "2019",
month = "1",
doi = "10.1111/liv.13948",
language = "English",
volume = "39",
pages = "81--89",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. / Kim, Hye Soo; Baatarkhuu, Oidov; Lee, Hye Won; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Song, Kijun; Han, Kwang Hyub; Kim, Beom Kyung; Kim, Seung Up.

In: Liver International, Vol. 39, No. 1, 01.2019, p. 81-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers

AU - Kim, Hye Soo

AU - Baatarkhuu, Oidov

AU - Lee, Hye Won

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Song, Kijun

AU - Han, Kwang Hyub

AU - Kim, Beom Kyung

AU - Kim, Seung Up

PY - 2019/1

Y1 - 2019/1

N2 - Background & Aims: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). Methods: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. Results: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). Conclusions: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.

AB - Background & Aims: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). Methods: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. Results: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). Conclusions: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85054307259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054307259&partnerID=8YFLogxK

U2 - 10.1111/liv.13948

DO - 10.1111/liv.13948

M3 - Article

C2 - 30280461

AN - SCOPUS:85054307259

VL - 39

SP - 81

EP - 89

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 1

ER -